Target $12.83 (was $12.83). The ACCC has a few issues with the purchase of Helathscope’s ((HSP)) pathology operations. UBS still thinks the deal will go through, but probably two months later than previously thought.
Small cuts to forecasts ensure, while the price target ticks up a little on peer multiple gains. Neutral call maintained.
Sector: Health Care Equipment & Services.
Target price is $12.85.Current Price is $12.48. Difference: $0.37 – (brackets indicate current price is over target). If SHL meets the UBS target it will return approximately 3% (excluding dividends, fees and charges – negative figures indicate an expected loss).